Skip to content

Change in AR at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$212.05M+8,382%
ALN
Alnylam PharmaceuticalsALNY
$110.42M+1,385%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
-$1.16M+5.5%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$7.91M+178%
Absci Corporation logo
Absci CorporationABSI
$0-100%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$65.78M-40.5%

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Reported directly by Assembly Biosciences in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's change in AR?
Assembly Biosciences (ASMB) reported change in AR of -$523K in Q1 2026.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.